Corbus Pharmaceuticals Holdings

CRBP · NASDAQ

$4.42−$0.04 (−0.90%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.46

CRBP analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $36.61 (+728.2% upside)

Low: $28.28
Now: $4.42
High: $50.40

Upgrades and downgrades

The latest rating actions, newest first

CRBP analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 14, 2026	Maintains	Buy	$35.00	41%
Oppenheimer	Aug 7, 2026	Maintains	Outperform	$52.00 → $48.00	33%
HC Wainwright & Co.	Aug 7, 2026	Maintains	Buy	$40.00 → $35.00	41%
Mizuho	Jun 23, 2026	Maintains	Outperform	$44.00 → $34.00	54%
Oppenheimer	Jun 17, 2026	Maintains	Outperform	$54.00 → $52.00	33%
Wedbush	May 27, 2026	Maintains	Outperform	$38.00 → $30.00	39%
HC Wainwright & Co.	May 26, 2026	Maintains	Buy	$40.00	41%
Mizuho	May 22, 2026	Maintains	Outperform	$40.00 → $44.00	54%
Jefferies	May 13, 2026	Maintains	Buy	$36.00 → $33.00	29%
Oppenheimer	May 13, 2026	Maintains	Outperform	$57.00 → $54.00	33%

The case for and against

Updated Oct 16, 2026

Bull case

Corbus Pharmaceuticals is attractive because CRB-913 showed a credible 5% mean weight loss at 60 mg by 12 weeks with no serious TRAEs, no suicidality, and only mild to moderate GI and psychiatric events, suggesting a differentiated, peripherally restricted CB1 mechanism that may avoid the historical toxicity of earlier agents. The obesity program also has commercial optionality, since the data support a possible monotherapy or incretin-combination role in a market where many patients do not respond to, tolerate, or remain on treatment with oral GLP-1s. Beyond obesity, CRB-701 adds a second catalyst with confirmed ORR of 42.9% in OPSCC and manageable safety across a 317-patient population, while TEMPO-1 and the September topline readout provide near-term validation paths.

Bear case

Corbus Pharmaceuticals is viewed negatively because its valuation rests on early-development assumptions that are highly sensitive to clinical success, regulatory approval, and future commercialization, all of which remain unproven for CRB-701 and CRB-913. The company also faces meaningful financing risk, since it may need additional equity funding to finish development, while competition from better-resourced biotech peers could pressure both market opportunity and execution. Even with modeled FY34 GAAP EPS of $7.90 and an NPV-based framework, the outlook is constrained by the possibility that efficacy, safety, or sales estimates fail to materialize.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.